The Gamaleya Center began clinical trials of a drug against coronavirus – RBC

Gunzburg announced the creation of a cure for coronavirus in December 2020. According to him, it will be used for droppers. After one or two doses of the drug, the patient should develop antibodies that will circulate in the blood for seven to ten days or longer.

The price of the drug will be several times higher than the coronavirus vaccine, Gunzburg warned.

Read on RBC Pro

He said that research could begin in the fall of 2021. However, November 10 stated that they would start in January 2022.

A drug based on the plasma of recovered COVID patients has passed clinical trials

Meanwhile, COVID-globulin, a drug based on antibodies to coronavirus isolated from the plasma of recovered people, has passed clinical trials and received a registration certificate from the Ministry of Health.

A double-blind, placebo-controlled comparative study showed that seven out of ten patients had a reduced risk of disease progression to a more severe form.

The drug is produced by the research and production association Microgen, which is part of the Nacimbio holding (a subsidiary of Rostec).

.

ttn-1

Bir yanıt yazın